Pancreatic Cancer Research

ResearcherUniversity of SalernoNo recent work listed

Vincenzo De Laurenzi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7506-1743; OpenAlex author ID A5017442589. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 9

  1. Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/cci.22.00160↗
  2. Proteomics Approach Highlights Early Changes in Human Fibroblasts-Pancreatic Ductal Adenocarcinoma Cells Crosstalk. Last author DOI 10.3390/cells11071160↗
  3. Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer. Last author DOI 10.1002/1878-0261.12492↗
  4. ABCC3 is a novel target for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.jbior.2019.04.004↗
  5. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. Co-author DOI 10.1186/s13046-019-1308-7↗
  6. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Co-author DOI 10.1038/s41388-018-0390-1↗
  7. Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8+ T cell number and tumour growth in pancreatic cancer. Last author DOI 10.1136/gutjnl-2017-314225↗
  8. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Co-author DOI 10.1038/ncomms9695↗
  9. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Co-author DOI 10.1016/j.ajpath.2012.07.016↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maria Caterina Turco · 6 shared papers, 2012–2023 · strength 0.49
  2. Verena Damiani · 5 shared papers, 2018–2022 · strength 0.45
  3. Alessandra Rosati · 5 shared papers, 2012–2023 · strength 0.34
  4. Margot De Marco · 5 shared papers, 2012–2023 · strength 0.34
  5. Liberato Marzullo · 4 shared papers, 2015–2023 · strength 0.32
  6. Aleksandra Adamska · 3 shared papers, 2018–2019 · strength 0.23
  7. Marco Falasca · 3 shared papers, 2018–2019 · strength 0.23
  8. Vittoria Iorio · 3 shared papers, 2015–2019 · strength 0.18
  9. Anna Maria Basile · 3 shared papers, 2015–2019 · strength 0.18
  10. Matthew A. Firpo · 2 shared papers, 2015–2023 · strength 0.17
  11. Alice Domenichini · 2 shared papers, 2019 · strength 0.17
  12. Riccardo Ferro · 2 shared papers, 2018–2019 · strength 0.15
  13. Josh M. Bleicher · 1 shared paper, 2023 · strength 0.14
  14. Kajsa E. Affolter · 1 shared paper, 2023 · strength 0.14
  15. Courtney L. Scaife · 1 shared paper, 2023 · strength 0.14
  16. Douglas G. Adler · 1 shared paper, 2023 · strength 0.14
  17. Sean J. Mulvihill · 1 shared paper, 2023 · strength 0.14
  18. Ignacio Garrido‐Laguna · 1 shared paper, 2023 · strength 0.14
  19. Katherine E. Poruk · 1 shared paper, 2023 · strength 0.14
  20. Pierluigi Di Sebastiano · 3 shared papers, 2012–2019 · strength 0.14
  21. Claudio Arra · 2 shared papers, 2015–2019 · strength 0.11
  22. Maria Carmela Pascale · 2 shared papers, 2015–2018 · strength 0.10
  23. Yulia Y. Maxuitenko · 1 shared paper, 2019 · strength 0.08
  24. Adam B. Keeton · 1 shared paper, 2019 · strength 0.08
  25. Gary Anthony Piazza · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.